Oruka Therapeutics Inc. Company Profile
NASDAQ: ORKAHealth CareBiotechnology: In Vitro & In Vivo Diagnostic SubstancesUSD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
Oruka Therapeutics at a glance
Oruka Therapeutics Inc. (NASDAQ: ORKA) is a Biotechnology: In Vitro & In Vivo Diagnostic Substances company in the Health Care sector headquartered in Menlo Park, CA. Oruka Therapeutics is led by Dr. Lawrence Otto Klein Ph.D. and employs about 68 people. At a market capitalization of $5.12 billion, it is considered a mid-cap company.
Its SEC Central Index Key (CIK) is 0000907654, which identifies the company's filings on EDGAR.
Summary generated from market data by MetaCap's automated system. Methodology
What does Oruka Therapeutics do?
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.
Business description based on the company's public filings.
Company information
- Legal name
- Oruka Therapeutics Inc.
- Ticker
- NASDAQ: ORKA
- Sector
- Health Care
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- CEO
- Dr. Lawrence Otto Klein Ph.D.
- Employees
- 68
- Headquarters
- 855 Oak Grove Avenue, Menlo Park, CA, United States
- Phone
- 650 606 7910
- Website
- orukatx.com
- Market cap
- $5.12B
- SEC CIK
- 0000907654
Companies similar to Oruka Therapeutics
| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| LNTHLantheus Holdings Inc. | 100.12 | -0.06% | $6.54B | vs ORKA |
| NEOGNeogen Corporation | 11.71 | +0.26% | $2.55B | vs ORKA |
| CLDXCelldex Therapeutics Inc. | 29.30 | -3.71% | $2.30B | vs ORKA |
| NTLAIntellia Therapeutics Inc. | 12.60 | +7.60% | $1.77B | vs ORKA |
| QDELQuidelOrtho Corporation | 12.41 | +0.81% | $851.02M | vs ORKA |
| ACHVAchieve Life Sciences Inc. | 7.19 | -0.69% | $741.31M | vs ORKA |
| TKNOAlpha Teknova Inc. | 8.44 | -3.10% | $453.13M | vs ORKA |
| MYGNMyriad Genetics Inc. | 4.20 | -1.87% | $401.73M | vs ORKA |